Expert Interview
Discussing the treatment landscape for diffuse large B-Cell Lymphoma and the uptake of ADC Therapeutics' Zynlonta
Ticker(s): ADCTInstitution: University of Miami
- Professor of Medicine and the Director of Lymphoma Program and Chief of Lymphoma Section at Sylvester Comprehensive Cancer Center at University of Miami.
- Research focuses on the pathogenesis of lymphoma, identification of molecular prognostic markers and elucidation of their role in determination of response to therapy, development of new lymphoma therapies.
- PI or Co-PI on numerous trials; his studies focus on diffuse large cell lymphoma, mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma, primary CNS lymphoma, lymphomas of the eye and other lymphoma subtypes.
Roughly how many patients do you manage with DLBCL?
Added By: c_adminGiven it's documented short time to response, what are your thoughts on using Zynlonta as a bridge to CAR-T therapy for those that maybe rapidly progressing?
Which future combinations in DLBCL do you see as most exciting? Which if any Zynlonta combinations are you most interested in? How interested in you about the potential of Zynlonta combined with a bispecific antibody?
Added By: jnelson3892Do you see potential for Zynlonta in any other NHL sub-types? Either alone or in combination?
Added By: jnelson3892Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
